Selected research
Industry Growth & Trends
Global Anti-TIGIT Antibody Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Anti-TIGIT Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Anti-TIGIT Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Anti-TIGIT Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-TIGIT Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Anti-TIGIT Antibody market include Arcus, Astellas, BMS, Compugen, Gilead Sciences, Mereo BioPharma, Seattle Genetics, AstraZeneca and BeiGene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Anti-TIGIT Antibody market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Anti-TIGIT Antibody market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Anti-TIGIT Antibody market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Anti-TIGIT Antibody.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Anti-TIGIT Antibody market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Anti-TIGIT Antibody Market by Company
Arcus
Astellas
BMS
Compugen
Gilead Sciences
Mereo BioPharma
Seattle Genetics
AstraZeneca
BeiGene
Hengrui Medicine
Junshi Biosciences
Roche
Merck
Innovent Biologics
Anti-TIGIT Antibody Segment by Type
Monotherapy
Combination Therapy
Anti-TIGIT Antibody Segment by Application
Cell Carcinoma
Solid Tumor
Anti-TIGIT Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-TIGIT Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-TIGIT Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-TIGIT Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Anti-TIGIT Antibody companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Monotherapy
- Combination Therapy
Applications
- Cell Carcinoma
- Solid Tumor
Companies covered
- Arcus
- Astellas
- BMS
- Compugen
- Gilead Sciences
- Mereo BioPharma
- Seattle Genetics
- AstraZeneca
- BeiGene
- Hengrui Medicine
- Junshi Biosciences
- Roche
- Merck
- Innovent Biologics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Anti-TIGIT Antibody Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Anti-TIGIT Antibody Market Size by Region (2021-2032)
- 1.4.1 Global Anti-TIGIT Antibody Market Size by Region (2021-2026)
- 1.4.2 Global Anti-TIGIT Antibody Market Size by Region (2027-2032)
- 1.5 Key Regions Anti-TIGIT Antibody Market Size (2021-2032)
- 1.5.1 North America Anti-TIGIT Antibody Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Anti-TIGIT Antibody Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Anti-TIGIT Antibody Market Size Growth Rate (2021-2032)
- 1.5.4 South America Anti-TIGIT Antibody Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Anti-TIGIT Antibody Market Size Growth Rate (2021-2032)
2 Anti-TIGIT Antibody Market by Type
- 2.1 Type Introduction
- 2.1.1 Monotherapy
- 2.1.2 Combination Therapy
- 2.2 Global Anti-TIGIT Antibody Market Size by Type
- 2.2.1 Global Anti-TIGIT Antibody Market Size Overview by Type (2021-2032)
- 2.2.2 Global Anti-TIGIT Antibody Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Anti-TIGIT Antibody Market Size Forecasted by Type (2027-2032)
- 2.3 Global Anti-TIGIT Antibody Market Size by Regions
- 2.3.1 North America Anti-TIGIT Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Anti-TIGIT Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Anti-TIGIT Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Anti-TIGIT Antibody Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Anti-TIGIT Antibody Market Size Breakdown by Type (2021-2026)
3 Anti-TIGIT Antibody Market by Application
- 3.1 Type Introduction
- 3.1.1 Cell Carcinoma
- 3.1.2 Solid Tumor
- 3.2 Global Anti-TIGIT Antibody Market Size by Application
- 3.2.1 Global Anti-TIGIT Antibody Market Size Overview by Application (2021-2032)
- 3.2.2 Global Anti-TIGIT Antibody Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Anti-TIGIT Antibody Market Size Forecasted by Application (2027-2032)
- 3.3 Global Anti-TIGIT Antibody Market Size by Regions
- 3.3.1 North America Anti-TIGIT Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Anti-TIGIT Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Anti-TIGIT Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Anti-TIGIT Antibody Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Anti-TIGIT Antibody Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Anti-TIGIT Antibody Industry Trends
- 4.2 Anti-TIGIT Antibody Industry Drivers
- 4.3 Anti-TIGIT Antibody Industry Opportunities and Challenges
- 4.4 Anti-TIGIT Antibody Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Anti-TIGIT Antibody Revenue (2021-2026)
- 5.2 Global Anti-TIGIT Antibody Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Anti-TIGIT Antibody Key Company Headquarters & Area Served
- 5.4 Global Anti-TIGIT Antibody Company, Product Type & Application
- 5.5 Global Anti-TIGIT Antibody Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Anti-TIGIT Antibody Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Anti-TIGIT Antibody Players Market Share by Revenue in 2025
- 5.6.3 2025 Anti-TIGIT Antibody Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Arcus
- 6.1.1 Arcus Company Information
- 6.1.2 Arcus Business Overview
- 6.1.3 Arcus Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Arcus Anti-TIGIT Antibody Product Portfolio
- 6.1.5 Arcus Recent Developments
- 6.2 Astellas
- 6.2.1 Astellas Company Information
- 6.2.2 Astellas Business Overview
- 6.2.3 Astellas Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Astellas Anti-TIGIT Antibody Product Portfolio
- 6.2.5 Astellas Recent Developments
- 6.3 BMS
- 6.3.1 BMS Company Information
- 6.3.2 BMS Business Overview
- 6.3.3 BMS Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 BMS Anti-TIGIT Antibody Product Portfolio
- 6.3.5 BMS Recent Developments
- 6.4 Compugen
- 6.4.1 Compugen Company Information
- 6.4.2 Compugen Business Overview
- 6.4.3 Compugen Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Compugen Anti-TIGIT Antibody Product Portfolio
- 6.4.5 Compugen Recent Developments
- 6.5 Gilead Sciences
- 6.5.1 Gilead Sciences Company Information
- 6.5.2 Gilead Sciences Business Overview
- 6.5.3 Gilead Sciences Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Gilead Sciences Anti-TIGIT Antibody Product Portfolio
- 6.5.5 Gilead Sciences Recent Developments
- 6.6 Mereo BioPharma
- 6.6.1 Mereo BioPharma Company Information
- 6.6.2 Mereo BioPharma Business Overview
- 6.6.3 Mereo BioPharma Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Mereo BioPharma Anti-TIGIT Antibody Product Portfolio
- 6.6.5 Mereo BioPharma Recent Developments
- 6.7 Seattle Genetics
- 6.7.1 Seattle Genetics Company Information
- 6.7.2 Seattle Genetics Business Overview
- 6.7.3 Seattle Genetics Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Seattle Genetics Anti-TIGIT Antibody Product Portfolio
- 6.7.5 Seattle Genetics Recent Developments
- 6.8 AstraZeneca
- 6.8.1 AstraZeneca Company Information
- 6.8.2 AstraZeneca Business Overview
- 6.8.3 AstraZeneca Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 AstraZeneca Anti-TIGIT Antibody Product Portfolio
- 6.8.5 AstraZeneca Recent Developments
- 6.9 BeiGene
- 6.9.1 BeiGene Company Information
- 6.9.2 BeiGene Business Overview
- 6.9.3 BeiGene Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 BeiGene Anti-TIGIT Antibody Product Portfolio
- 6.9.5 BeiGene Recent Developments
- 6.10 Hengrui Medicine
- 6.10.1 Hengrui Medicine Company Information
- 6.10.2 Hengrui Medicine Business Overview
- 6.10.3 Hengrui Medicine Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Hengrui Medicine Anti-TIGIT Antibody Product Portfolio
- 6.10.5 Hengrui Medicine Recent Developments
- 6.11 Junshi Biosciences
- 6.11.1 Junshi Biosciences Company Information
- 6.11.2 Junshi Biosciences Business Overview
- 6.11.3 Junshi Biosciences Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Junshi Biosciences Anti-TIGIT Antibody Product Portfolio
- 6.11.5 Junshi Biosciences Recent Developments
- 6.12 Roche
- 6.12.1 Roche Company Information
- 6.12.2 Roche Business Overview
- 6.12.3 Roche Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Roche Anti-TIGIT Antibody Product Portfolio
- 6.12.5 Roche Recent Developments
- 6.13 Merck
- 6.13.1 Merck Company Information
- 6.13.2 Merck Business Overview
- 6.13.3 Merck Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Merck Anti-TIGIT Antibody Product Portfolio
- 6.13.5 Merck Recent Developments
- 6.14 Innovent Biologics
- 6.14.1 Innovent Biologics Company Information
- 6.14.2 Innovent Biologics Business Overview
- 6.14.3 Innovent Biologics Anti-TIGIT Antibody Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Innovent Biologics Anti-TIGIT Antibody Product Portfolio
- 6.14.5 Innovent Biologics Recent Developments
7 North America
- 7.1 North America Anti-TIGIT Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 7.3 North America Anti-TIGIT Antibody Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Anti-TIGIT Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 8.3 Europe Anti-TIGIT Antibody Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Anti-TIGIT Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Anti-TIGIT Antibody Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Anti-TIGIT Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 10.3 South America Anti-TIGIT Antibody Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Anti-TIGIT Antibody Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Anti-TIGIT Antibody Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst